Вісник проблем біології і медицини (Mar 2022)

DYNAMICS OF OSTEOACTIVIN IN PATIENTS WITH OSTEOPOROTIC FRACTURES

  • Azizova G. I.,
  • Hasanova N. A.,
  • Dadashova A. R.

DOI
https://doi.org/10.29254/2077-4214-2022-1-163-119-122
Journal volume & issue
no. 1
pp. 119 – 122

Abstract

Read online

The study examines the dynamics of a regulatory protein called osteoactivin in the blood serum of patients with osteoporosis and osteoporotic fractures. Patients applying to the Traumatology Department of the Azerbaijan Scientific Research Institute of Traumatology and Orthopedics were included in the research material. Patients in this study had osteoporosis diagnosis in anamnesis and frequent osteoporotic fractures, as well as signs of osteoporosis and related complaints. The diagnosis was confirmed by densitometry and X-ray. 68 people from 38 to 83 years of age who meet the admission criteria were selected and divided into 4 groups: Group I – control group – 14 practically healthy people, Group II – 14 patients with osteoporosis, Group III – 15 patients with non-osteoporotic fractures, Group IV – 25 patients with osteoporotic fractures. Patients were measured for serum osteoactivin 3 times: on the first day, 10 days later, and 1 month later. Results. According to the results, in the first and subsequent 10 days in 13 out of 14 patients with osteoporosis, there was an increase in concentration of GPNMB, while remaining one patient witnessed a decline in this indicator. After 1 month, 12 out of 14 patients showed an increase relative to initial levels. In all patients with fractures not associated with osteoporosis, the content of GPNMB in the first and in 10 days increased by a statistically significant value. At the same time, comparison of GPNMB concentrations in blood serum in the first day and after 1 month yielded a similar result. Nevertheless, there was no statistically significant difference in the dynamics of osteoactivin in patients with osteoporotic fractures (p>0,001). Following the dynamics for 1 month, it is impossible to think about the effectiveness of treatment during the recovery period. This requires more long-term and extensive research to monitor the dynamics of GPNBM during the full recovery of osteoporotic fractures.

Keywords